Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label, Multicenter, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Mixed-Depth, Full-Thickness Burn Wounds as an Alternative to Autografting

NCT06223269 is registered in ClinicalTrials.gov with XenoTherapeutics, Inc. as lead sponsor.

NCT NCT06223269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label, Multicenter, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Mixed-Depth, Full-Thickness Burn Wounds as an Alternative to Autografting
Lead sponsor
XenoTherapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
May 9, 2024
Completion date
January 31, 2026
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

burn (disorder), burn degree second, burns degree third, thermal burn, wound heal